DR Congo to receive 70,000 doses of Ervebo vaccine as Ebola infections surge
The Democratic Republic of the Congo is set to receive 70,000 doses of the Ervebo vaccine to combat a severe Ebola outbreak caused by the Bundibugyo virus. While Ervebo is not specifically licensed for this strain, the WHO is initiating clinical trials to test its efficacy.
Why it matters
This is a critical public health intervention in a region facing a major humanitarian and medical crisis.
WHO says vaccines for Ebola virus disease being allocated to DRC amid largest outbreak that has killed nearly 2,500.
x whatsapp-stroke copylink google Add Al Jazeera on Google info A vial of the Ebola vaccine Ervebo during a previous outbreak of the disease in Sierra Leone [File: AFP] By Anadolu , AP and Reuters Published On 20 Aug 2026 20 Aug 2026 As the Democratic Republic of the Congo (DRC) struggles to manage its largest outbreak of the Ebola virus, it is set to receive 70,000 doses of the Ervebo vaccine which has been effective in previous epidemics.
The World Health Organization (WHO) said on Thursday that the doses have been allocated from the global Ebola virus disease vaccine stockpile and would include 20,000 shots to be used in a late-stage trial to understand the impact of the vaccine on the Bundibugyo virus.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in